TriangleZanzalintinib (NCT07193550)
Zanzalintinib trial for Bone Sarcomas (NCT07193550). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with unresectable or metastatic bone sarcoma after earlier systemic treatment, unless no standard option exists. Eligible groups are osteosarcoma, Ewing sarcoma, higher-grade conventional chondrosarcoma and other primary bone sarcomas. Soft-tissue Ewing sarcoma also qualifies.
The idea: test daily oral zanzalintinib, which blocks growth signals and signals that help tumors form blood vessels. Prior VEGF-targeting kinase inhibitors exclude participation. Researchers assess safety and cancer control; conventional chondrosarcoma requires recent progression. Research-sample enrollment is required.
This phase 2 study plans 70 patients. John Livingston leads MD Anderson's recruiting Houston site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.